| Name | Title | Contact Details |
|---|---|---|
Brian Silver |
Chief Financial Officer | Profile |
Leiden Dworak |
Vice President, Finance | Profile |
David Southwell |
Chief Executive Officer | Profile |
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.